Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

Temporal trends in venous thromboembolism after radical cystectomy.

Lyon TD, Tollefson MK, Shah PH, Bews K, Frank I, Karnes RJ, Thompson RH, Habermann EB, Boorjian SA.

Urol Oncol. 2018 Jun 6. pii: S1078-1439(18)30167-4. doi: 10.1016/j.urolonc.2018.05.015. [Epub ahead of print]

PMID:
29885792
2.

Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.

Bhindi B, Karnes RJ.

Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30370-1. doi: 10.1016/j.eururo.2018.05.021. [Epub ahead of print] No abstract available.

PMID:
29866462
3.

The Association of Aspirin Use with Survival Following Radical Cystectomy.

Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

J Urol. 2018 May 29. pii: S0022-5347(18)43297-1. doi: 10.1016/j.juro.2018.05.119. [Epub ahead of print]

PMID:
29857079
4.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 May 14. doi: 10.1158/1078-0432.CCR-17-2745. [Epub ahead of print]

PMID:
29760221
5.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

6.

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P.

World J Urol. 2018 May 2. doi: 10.1007/s00345-018-2299-2. [Epub ahead of print]

PMID:
29721611
7.

Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.

Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC.

J Urol. 2018 Apr 27. pii: S0022-5347(18)43071-6. doi: 10.1016/j.juro.2018.04.070. [Epub ahead of print]

PMID:
29709664
8.

Examining the association between adiposity and biochemical recurrence after radical prostatectomy.

Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK.

Can Urol Assoc J. 2018 Mar 19. doi: 10.5489/cuaj.4923. [Epub ahead of print]

PMID:
29603915
9.

More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.

Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA.

Eur Urol. 2018 Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12.

PMID:
29544737
10.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
11.

Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.

EMBO Mol Med. 2018 Apr;10(4). pii: e8478. doi: 10.15252/emmm.201708478.

12.

Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA.

J Cancer Res Clin Oncol. 2018 May;144(5):883-891. doi: 10.1007/s00432-018-2615-7. Epub 2018 Mar 6.

PMID:
29511883
13.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

PMID:
29453313
14.

Is it time for a more 'proactive' approach to metastatic prostate cancer?

Soligo M, Sharma V, Karnes RJ.

BJU Int. 2018 Feb;121(2):167-168. doi: 10.1111/bju.14107. No abstract available.

PMID:
29359528
15.

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.

PMID:
29307681
16.

Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.

Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ.

Eur Urol Focus. 2018 Jan 3. pii: S2405-4569(17)30292-4. doi: 10.1016/j.euf.2017.12.005. [Epub ahead of print]

PMID:
29306730
17.

The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy.

Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK.

Clin Genitourin Cancer. 2018 Jun;16(3):e629-e636. doi: 10.1016/j.clgc.2017.11.003. Epub 2017 Dec 6.

PMID:
29289518
18.

A House Divided: The Irradiation Versus Prostatectomy Debate Continues.

Zaid HB, Karnes RJ.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):512-514. doi: 10.1016/j.ijrobp.2017.01.220. No abstract available.

PMID:
29280441
19.

Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse.

Zattoni F, Morlacco A, Nehra A, Frank I, Boorjian SA, Thapa P, Karnes RJ.

Int Braz J Urol. 2018 May-Jun;44(3):491-499. doi: 10.1590/S1677-5538.IBJU.2017.0376.

20.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
21.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
22.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
23.

Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Gearman DJ, Morlacco A, Cheville JC, Rangel LJ, Karnes RJ.

J Urol. 2018 May;199(5):1188-1195. doi: 10.1016/j.juro.2017.11.116. Epub 2017 Dec 7.

PMID:
29225057
24.

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.

Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ.

Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28.

PMID:
29195777
25.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
26.

PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.

Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W.

Clin Cancer Res. 2018 Feb 15;24(4):834-846. doi: 10.1158/1078-0432.CCR-17-2006. Epub 2017 Nov 22.

27.

Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.

Murphy SJ, Kosari F, Karnes RJ, Nasir A, Johnson SH, Gaitatzes AG, Smadbeck JB, Rangel LJ, Vasmatzis G, Cheville JC.

Cancer Res. 2017 Nov 15;77(22):6157-6167. doi: 10.1158/0008-5472.CAN-17-0529. Epub 2017 Nov 10.

PMID:
29127096
28.

Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series.

Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ.

Urology. 2018 Feb;112:29-32. doi: 10.1016/j.urology.2017.10.016. Epub 2017 Oct 25.

PMID:
29079212
29.

Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.

Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, Briganti A.

Eur Urol. 2018 Jun;73(6):890-896. doi: 10.1016/j.eururo.2017.09.027. Epub 2017 Oct 16.

PMID:
29042125
30.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.

Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14. Review.

PMID:
29037513
31.

Prostatectomy versus Observation for Early Prostate Cancer.

Sharma V, Karnes RJ.

N Engl J Med. 2017 Sep 28;377(13):1302. doi: 10.1056/NEJMc1710384. No abstract available.

PMID:
28953432
32.

Author Reply.

Bhindi B, Karnes RJ.

Urology. 2017 Nov;109:152. doi: 10.1016/j.urology.2017.06.056. Epub 2017 Sep 21. No abstract available.

PMID:
28943048
33.

LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.

Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH.

Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.

PMID:
28916652
34.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.09.033. [Epub ahead of print]

PMID:
28916273
35.

Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.

Mason RJ, Frank I, Bhindi B, Tollefson MK, Thompson RH, Karnes RJ, Tarrell R, Thapa P, Boorjian SA.

World J Urol. 2017 Dec;35(12):1879-1884. doi: 10.1007/s00345-017-2087-4. Epub 2017 Sep 14.

PMID:
28913657
36.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
37.

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.

Oncotarget. 2017 Feb 7;8(31):50804-50813. doi: 10.18632/oncotarget.15133. eCollection 2017 Aug 1.

38.

Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.

Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, Frank I, Griebling TL, Tollefson MK, Thompson RH, Holzbeierlein JM, Karnes RJ, Boorjian SA.

Clin Genitourin Cancer. 2017 Aug 1. pii: S1558-7673(17)30208-2. doi: 10.1016/j.clgc.2017.07.011. [Epub ahead of print]

PMID:
28844793
39.

The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40.

Weight CJ, Narayan VM, Smith D, Kim SP, Karnes RJ.

Urology. 2017 Dec;110:127-133. doi: 10.1016/j.urology.2017.08.012. Epub 2017 Aug 24.

PMID:
28842211
40.

Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin.

Bhindi B, Carlson RE, Mason RJ, Schulte PJ, Gettman MT, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Leibovich BC, Karnes RJ.

Urology. 2017 Nov;109:145-152. doi: 10.1016/j.urology.2017.06.054. Epub 2017 Aug 18.

PMID:
28823636
41.

Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy.

Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH, Tollefson MK, Boorjian SA, Pagliaro LC, Karnes RJ.

Clin Genitourin Cancer. 2017 Jul 22. pii: S1558-7673(17)30207-0. doi: 10.1016/j.clgc.2017.07.010. [Epub ahead of print]

PMID:
28818551
42.

Editorial Comment.

Colicchia M, Karnes RJ.

J Urol. 2017 Nov;198(5):1084. doi: 10.1016/j.juro.2017.06.101. Epub 2017 Aug 8. No abstract available.

PMID:
28801257
43.

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.

Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

PMID:
28779974
44.

The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.

Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

Eur Urol Focus. 2017 Jan 17. pii: S2405-4569(17)30002-0. doi: 10.1016/j.euf.2016.12.008. [Epub ahead of print]

PMID:
28753838
45.

Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.

Moschini M, Morlacco A, Briganti A, Hu B, Colombo R, Montorsi F, Frank I, Daneshmand S, Karnes RJ.

Eur Urol Focus. 2016 Nov 23. pii: S2405-4569(16)30163-8. doi: 10.1016/j.euf.2016.11.005. [Epub ahead of print]

PMID:
28753820
46.

Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells.

Sharma V, Dong H, Kwon E, Karnes RJ.

Eur Urol Focus. 2018 Jan;4(1):75-79. doi: 10.1016/j.euf.2016.09.003. Epub 2016 Sep 21.

PMID:
28753790
47.

Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.

Moschini M, Fossati N, Sood A, Lee JK, Sammon J, Sun M, Pucheril D, Dalela D, Montorsi F, Karnes RJ, Briganti A, Trinh QD, Menon M, Abdollah F.

Eur Urol Focus. 2018 Jan;4(1):68-74. doi: 10.1016/j.euf.2016.06.001. Epub 2016 Jun 14.

PMID:
28753764
48.

Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals.

Gershman B, Psutka SP, McGovern FJ, Dahl DM, Tabatabaei S, Gettman MT, Frank I, Carlson RE, Rangel LJ, Barry MJ, Blute ML, Karnes RJ.

Eur Urol Focus. 2016 Jun;2(2):172-179. doi: 10.1016/j.euf.2015.06.011. Epub 2015 Jul 15.

PMID:
28723533
49.

Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.

Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ.

Eur Urol Focus. 2016 Dec;2(5):522-531. doi: 10.1016/j.euf.2016.01.008. Epub 2016 Feb 10.

PMID:
28723518
50.

The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis.

Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, Hamilton RJ, Kulkarni GS, Finelli A, Fleshner NE, Boorjian SA, Karnes RJ.

JAMA Intern Med. 2017 Sep 1;177(9):1273-1286. doi: 10.1001/jamainternmed.2017.2791.

PMID:
28715534

Supplemental Content

Loading ...
Support Center